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What’s already known about this topic?  
• Currently there is a lack of consensus on the diagnosis of epidermolysis bullosa 
acquisita (EBA).  
 
What does this study add?  
• These recommendations, which have been developed by international experts, 
provide appropriate pathways for the EBA diagnosis: the algorithms may be used to 





Epidermolysis bullosa acquisita (EBA) is a complex autoimmune bullous disease disease with 
variable clinical presentations and multiple possible diagnostic tests making an international 
consensus on diagnosis of EBA needed. 
Objectives  
To obtain an international consensus on the clinical and diagnostic criteria for EBA. 
Methods  
The international bullous diseases group (IBDG) met three times to discuss the clinical and 
diagnostic criteria for EBA. For the final voting exercise, 22 experts from 14 different 
countries voted on 50 different items. When more than 30% disagreed with a proposal, a 
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48/50 proposals achieved consensus after discussion. This included 9 diagnostic criteria that 
are summarized in a flow chart. The IBDG was unable to determine one procedure which 
would be applicable worldwide 
Limitations  
Differential diagnosis of bullous systemic lupus erythematosus has not been addressed.   
Conclusion  
This first international consensus conference established generally agreed upon clinical and 
laboratory criteria defining the clinical classification and diagnostic testing for EBA. Holding 
these voting exercises in person with the possibility of discussion prior to voting has 
advantages in reaching consensus over Delphi exercises with remote voting.  
 
Introduction 
The International Bullous Diseases Group (IBDG) was formed in 2005 following a 
research meeting at the National Institutes of Health for experts in blistering diseases to 
work towards a consensus for the development and validation of definitions and outcome 
measures in autoimmune bullous diseases (AIBD).1 The IBDG focused its efforts initially on 
pemphigus with consensus definitions, development, and validation of the Pemphigus 
Disease Area Index (PDAI) and the Autoimmune Bullous Skin Intensity Score (ABSIS).1,2 
Subsequently, the IBDG has published consensus definitions for bullous pemphigoid (BP) 
and proposed the BP Disease Area Index (BPDAI) severity tool, 3 and then consensus 
definitions for mucous membrane (MM) pemphigoid (MMP) and the MMP Disease Area 
Index (MMPDAI).4 The current project relates to international consensus definitions on 
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Two cases of an adult-onset, acquired blistering disease that was reminiscent of 
patients with hereditary dystrophic epidermolysis bullosa (EB) were reported in 1895 by 
Elliott.5 A landmark paper on the subject was in 1971 by Roenigk and colleagues who 
described three new cases of EBA, reviewed the world literature and proposed the first 
diagnostic criteria for EBA.6 These criteria were soon modified by the advent of 
immunofluorescence (IF) and the finding that all EBA patients had immunoglobulins (Ig) IgG 
and sometimes C3 deposits in their dermal-epidermal junction (DEJ) and that by 
immunoelectron microscopy (IEM), these DEJ immune deposits were clearly in a different 
localization than immune deposits observed in BP.7-10 The IgG autoantibodies (auto-Ab) 
accounting for these DEJ immune deposits were found to be auto-Ab directed against a 290 
kDa protein, type VII collagen (Col7), the major component of anchoring fibrils  (AFs) in the 




The IBDG met three times during 2015: at the annual meetings of the American 
Academy of Dermatology in San Francisco (21 experts from 11 countries), the European 
Society of Dermatological Research in Rotterdam (11 experts from 6 countries), and the 
European Academy of Dermatology and Venereology in Copenhagen (22 experts from 14 
countries). Initial presentations and discussions took place at the first two meetings. After 
further revisions and discussions at the third meeting, consensus voting took place on the 
definitions and diagnostic techniques. We defined "consensus" according to Harmonize 
Outcome Measures for Eczema (HOME) by having less than one-third of the key opinion 










This article is protected by copyright. All rights reserved. 
were put forward for discussion and voting related to the diagnostic processes involved in 
EBA. For each proposal, participants could ‘agree’, be ‘undecided’ or ‘disagree’. Tables 
summarizing the literature (supplementary tables II to VI) and examples of cases of EBA 
(supplementary data 1) were presented for the discussion.  
 
Results  
Altogether, 38 experts in EBA from 15 countries took part in this consensus, although 
not all were able to attend all 3 international meetings held in San Francisco, Rotterdam and 
Copenhagen. The actual results of the voting questions (supplementary table VII) and the 
reported anonymized results in the final version of the approved wording or procedures 
were from 22 blistering disease experts from 14 different countries (Supplementary Fig 1). 
Although not all members of the IBDG were present at the final voting meeting, all co-
authors are concordant with the EBA diagnostic criteria herein.  
 
Definition and clinical variants of EBA 
EBA is defined as a subepithelial AIBD in which patients have tissue-bound auto-
antibodies (Ab) targeted against Col7 within AFs of the basement membrane zone (BMZ) of 
DEJ or chorio-epithelial junction (CEJ) in stratified squamous epithelia. 
Several forms of EBA exist, with two major types termed: (1) the classical/ 
mechanobullous form and (2) the non classical/ non mechanobullous forms, first described 
by Gammon WR et al in 1982.18 The latter includes forms which may clinically resemble BP, 
MMP, Brunsting-Perry pemphigoid and linear IgA bullous dermatosis (LABD).6, 18-35 Table I 
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frequency of these subtypes varies in different countries with the classical type being the 
most common in European reports and the BP-like form more common in Asia 
(Supplementary Table II).36-39 It should be recognized that overlapping clinical presentations 
also may occur (proposal 09, supplementary cases 1 to 5). Overall, because EBA can appear 
clinically, histologically, and immunologically similar to BP, 18, 20-24 when the initial diagnostic 
consideration of the dermatologist is BP, EBA should also be considered. Further, if certain 
clinical clues are somewhat atypical for BP (such as lesions that heal with scarring and milia 
formation, head and neck involvement, mucosal involvement, disease onset younger than 
70), 40  the diagnostic possibility that the patient has EBA, rather than BP, rises considerably. 
Lastly, it is important to classify MM predominant EBA (MM-EBA) cases because the severity 
of the mucosal involvement dictates more aggressive, multidisciplinary management.   
There has been confusion in the literature as to which forms constituted an 
‘inflammatory’ form of EBA.13,20,22,23,36-39 The consensus members agreed that the BP-like 
form is inflammatory but both MM-EBA and IgA-EBA may be inflammatory as well.  On the 
other hand, Brunsting-Perry like EBA is usually a non-inflammatory form of EBA.   
 
Laboratory testing for EBA 
The IBDG reached agreement on the following proposal: routine histopathology, 
direct IF (DIF) microscopy and indirect IF (IIF) that are laboratory tests widely available, allow 
a diagnosis of subepithelial AIBD but are not able to distinguish EBA from another 
subepidermal AIBD. Routine histopathology on a biopsy obtained from lesional skin or MM 
of an EBA patient shows: (i) subepidermal or subepithelial cleavage, (ii) a great variability in 
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Routine DIF microscopy of perilesional skin or MM shows (i) linear immune deposits along 
the BMZ of DEJ or CEJ and (ii) no labelling of dermal blood vessels. The profile of immune 
deposits includes IgG and C3 but occasionally IgA or IgM (Supplementary Table III, 
supplementary case report 5).41-43 Routine IIF microscopy on monkey, rat or rabbit 
esophagus or human skin can detect anti-BMZ auto-Ab, but it is often at a low titer.   
Currently, the diagnosis of EBA should be confirmed by at least one of the following 
tests that are only performed in academic centers and are not widely available to the 
average dermatologist worldwide: 13,15,35 (A) among tests requiring skin or MM biopsies: 
electron microscopy (EM) and direct IEM,44 serration pattern analysis by DIF, 41,45,46 and 
Fluorescent Overlay Antigen Mapping (FOAM), 47-49 and (B) among serological tests for 
detection of circulating auto-Ab to Col7: ELISA, IIF on BIOCHIP with Col7-NC1 transfected 
human cells, 50  immunoblotting (IB), IIF on skin deficient in Col7, 51,52 and/ or indirect IEM. 44 
All these serological tests obviously require that the EBA patient have auto-Ab to Col7 
circulating in their blood and it must keep in mind that anti-Col7 auto-Ab are also present in 
bullous systemic lupus erythematosus (BSLE).53 
Alternative laboratory tests when none of these tests is available include: DIF and IIF 
on SSS,54 but they will not absolutely clinch the diagnosis of EBA. 55,56 
 
Standard transmission EM and IEM 
 In EBA patients, standard transmission EM shows an electron-dense band 
immediately below the lamina densa (LD) in the AF zone. Another EM finding suggesting 
EBA is that the cleavage occurs below the LD which remains attached to the roof of the 
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  Direct IEM on perilesional skin shows in vivo bound immune deposits which are very 
thick, located in the AF zone and a cleavage under immune deposits, if it is present (Fig 3).44 
The IBDG did agree on the limitations of direct IEM (proposal 29). Sixteen members of the 
consensus group attending the EADV voting had EM available at their site, but only about 
half of the group had experience in using EM and only 7 were currently using IEM.  
 
Serration pattern analysis.  
DIF microscopy of a perilesional skin biopsy can distinguish EBA from other sub-
epithelial AIBD by showing an u-serrated linear pattern of Ig deposits along the BMZ in EBA 
and BSLE and a n-serrated pattern of Ig deposits in BP, anti-laminin 332 MMP and anti-
p200/laminin1 pemphigoid (Fig 2).41,45,46,55,56  No agreement was obtained on limitations of 
the serration pattern analysis (proposal 26). Indeed it can be performed with routine DIF 
microscopy (new unpublished data on exact requirements in supplementary data 2). 
However, to date this test is not widely available and only the teams in Groningen and 
Lubeck have been able so far to master the technique (proposal 26bis).  
 
Fluorescent Overlay Antigen Mapping analysis 
FOAM, using routine IF microscope with either an image analysis system47 or a laser 
scanning confocal microscopy48,49, shows in EBA in vivo bound immune deposits below basal 
keratinocytes membrane, lamina lucida and LD components (Fig 4).  
 
ELISA 
Commercially available ELISAs using recombinant NC1/NC2-Col7, 57-60 or NC1-Col7,50 
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96.7%) on preselected positive sera by IIF on SSS, with floor labelling (Supplementary Table 
IV). The sensitivity of ELISA to NC1/NC2 is lower (30-54%) in studies on unselected EBA 
sera.39, 61  
ELISA using a full-length Col7 is more sensitive than ELISA using NC1/NC2-Col7 but 
not commercially available (Supplementary Table V).39,42,62,63  
ELISA Col7 are not highly specific since they may be positive in patients with Crohn’s 
disease or ulcerative colitis without cutaneous manifestations of EBA,64 atypical AIBD,65 and 
patients with recessive dystrophic EB (RDEB) (Supplementary Tables V, VI). 39,63,66,67 Of note, 
the presence of circulating auto-Ab against BP180, laminin 332, the p200/laminin 1chain 
(detected by IB or ELISA), which may occur due to the epitope spreading phenomenon, does 
not rule out the diagnosis of EBA (Supplementary cases 2 and 4).37,68-75 
 
Novel technique: IIF microscopy using Col7-NC1 transfected cells  
Patient serum autoAb could label Col7-NC1 transfected cells on a special slide, a so-
called BIOCHIPTM method (Fig 5). This test is now commercially available and could be used 
as a substitute for the ELISA outlined above. It is a sensitive, specific and rapid assay for 
testing preselected positive sera by IIF on SSS, with floor labelling.50 Like serological testing 
by ELISA, its sensitivity is lower in studies on unselected EBA sera.39  
 
Immunoblotting 
IB is a serological technique performed on extracts of tissues or cells or recombinant 
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sera that labels the Col 7 -chain.  IB can substitute for the commercially available ELISA. 
The IBDG did agree on the limitations of IB (proposal 33).  
 
IIF on Col7-deficient human skin and indirect IEM 
A definitive diagnosis of EBA can be demonstrated by IIF when presumptive EBA sera 
that label the DEJ of normal human skin, but do not label skin from generalized severe RDEB 
with absent Col7 (Fig 7).51,52 Obviously, this is not offered in commercial laboratories and is 
limited by the access to skin specimens from patients with exceedingly rare diseases.  
A definitive diagnosis of EBA can also be demonstrated when presumptive EBA sera 
label the AFs by indirect IEM (Fig 3).44  
 
DIF and IIF microscopy on SSS 
DIF and IIF on SSS are alternative laboratory tests which only give a probable 
diagnosis of EBA. DIF is performed after splitting the skin biopsy of the patient using 1M 
NaCl (Supplementary data 3).54,76 It is not possible with MM biopsies. IIF may be performed 
on either normal human SSS using a similar procedure, 119,77-79 or monkey SSS, which is 
commercially available. Immune deposits in EBA patients remain on the dermal floor of the 
separation, while BP immune deposits remain with the epidermal roof (Fig 8). However, this 
dermal labelling is not specific to EBA. It is also seen in anti-laminin 332 MMP and anti-
p200/ laminin 1 pemphigoid (Fig 4). Additional tests are necessary to exclude reactivity 
against these molecules and finally diagnose an EBA. Overall, IIF on SSS is more sensitive 
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Lastly, the IBDG updated consensus criteria for EBA diagnosis (2015) include 
combinations of the following tests:  
1. A bullous disorder within the defined clinical spectrum 
2. Histopathology revealing a subepidermal or subepithelial blister 
3. A positive DIF microscopy of perilesional skin or MM with linear IgG, C3, IgA and/or 
IgM deposits within the epithelial BMZ 
4. Detection of circulating auto-Ab against Col7 by IB, ELISA and/or IIF microscopy on 
Col7-expressing human cells  
5. Labelling AFs by indirect IEM or negative IIF microscopy on Col7-deficient skin 
6. An u-serration pattern by DIF microscopy  
7. Direct IEM of perilesional skin demonstrating immune deposits within AFs zone +/-
the lower LD. 
8. In vivo bound immune deposits below type IV collagen by FOAM 
9. Alternatively to item 4 to 8, dermal labelling by DIF and/or IIF on SSS 
 
The IBDG did reach agreement that the ideal scenario is for a putative EBA disease 
patient (criteria 1) to exhibit a sub-epidermal bulla by histology (criteria 2 optional), a 
positive DIF microscopy (criteria 3), and an ELISA (or another serological test) showing that 
the patient's serum auto-Ab targets col7 (criteria 4 or 5). In this scenario, a highly probable 
diagnosis of EBA has been made and no further tests need to be done for confirmation. 
Unlike this ideal scenario for the diagnosis of EBA, the problem that often arises39, 61 is when 
an EBA patient lacks circulating auto-antibodies and therefore IIF, SSS IIF and ELISA are 
negative. Then the diagnosis of EBA could be considered definitive if items 1 and 3 and at 
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not be done, the diagnosis of EBA is possible if items 1, 3 and 9 are present; then diagnosis 
has to be confirmed by exclusion of auto-immunity against laminin 332 or the p200/laminin 
1 chain. The consensus conference was not able to determine one procedure which would 
be applicable for the whole world. There was an animated discussion about what should be 
considered routine (Proposal 18). Which test(s) that the practitioner chooses will likely be 
determined by the clinical presentation of the patient (classical/mechanobullous type or 
not), the geography of the practitioner and which test is most logistically accessible. Figure 9 
is a flow diagram summarizing the different diagnostic investigative pathways.  
 
In conclusion, this consensus of the criteria for the diagnosis of EBA provides a 
general framework for establishing the diagnosis of EBA and takes into account the clinical 
presentation and available laboratory testing. These criteria should help clinicians from mis-
diagnosing other AIBDs and missing the diagnosis of EBA. They will also be useful for future 
studies designed to define the natural history and therapeutic outcomes of EBA.   
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Figure Legends 
Figure 1. Clinical subtypes of epidermolysis bullosa acquisita (EBA). A-G, Classical / 
mechanobullous form of EBA: trauma induced lesions are preferably localized to the 
extensor skin surfaces i.e dorsal hands (A, B), feet (C), heel (D), elbows (E) and knees (F). 
Bullous/vesicular lesions or erosions are surrounded by non-inflamed or scarred skin (B, D). 
Lesions heal with scarring (E, F) and milia formation (A, B, F). Nail dystrophy (C) and scarring 
alopecia (G) are possible. H-J, bullous pemphigoid (BP)-like form of EBA: tense bullae on 
erythematous (H) or urticarial skin (I, J) suggestive of BP, in atypical locations for BP at 
extensor areas of the limbs (H-J). K-P, Mucous membrane (MM) EBA: all the MM lined by 
squamous epithelium may be involved, particularly the tongue in buccal MM (K), anus (L), 
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stenosis (P). Q, IgA EBA with bullous eruption in a “string of pearls”. R, Brunsting-Perry type 
EBA with recurrent blistering dermatosis confined to the head for ten years. Fig 1-C, 1-M, 
and 1-O = Fig. 61.1b, 61.1c and 61.1d in Prost–Squarcioni C and Caux F. Management of 
epidermolysis bullosa acquisita, in Murrell D ed.  Blistering Disease: Clinical Features, 
Pathogenesis, Treatment. New York, NY: Springer 2015, with the permission of Springer, 1-H 
=  Fig. 40.2a in Prost–Squarcioni C and Caux F. Clinical presentation of epidermolysis bullosa 
acquisita in Murrell D ed.  Blistering Disease: Clinical Features, Pathogenesis, Treatment. 
New York, NY: Springer 2015, with the permission of Springer, 1-G = supplementary fig 1a in 
Zumelzu C et al. Black patients of African descent and HLA-DRB1*15:03 frequency 
overrepresented in epidermolysis bullosa acquisita. J Invest Dermatol. 2011,131:2386-93 
with the permission of J Invest Dermatol, 1-P courtesy of Prof Michel Brauner. 
 
Figure 2. Serration pattern analysis by direct immunofluorescence. The u-serrated pattern is 
characterized by closed arches at the bottom appearing like “growing grass”, while the n-
serrated pattern shows closed arches at the top. A, direct immunofluorescence of 
epidermolysis bullosa acquisita skin showing linear IgG deposition along the epidermal 
BMZ in an u-serrated pattern (400x). B, direct immunofluorescence of bullous pemphigoid 
skin showing linear IgG deposition along the epidermal BMZ in a n-serrated pattern (400x). 
Courtesy of Dr Gilles Diercks. 
 
Figure 3. Immunoelectron microscopy (IEM) in epidermolysis bullosa acquisita. A, direct IEM 
in pre-embedding immunoperoxidase technique. Thick immune deposits are observed in the 
anchoring fibril zone below the lamina densa (LD) and split (*) under them. B and C, indirect 
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deposits (arrows) decorate the ends of anchoring fibrils. 2A,  2B and 2C = Fig. 19.10b, 19.12a 
and 19.12b in Prost–Squarcioni C. Electron microscopy and immunoelectron microscopy, in 
Murrell D ed.  Blistering Disease: Clinical Features, Pathogenesis, Treatment. New York, NY: 
Springer 2015, with the permission of Springer  
Figure 4. Fluorescent overlay antigen mapping (FOAM) in skin biopsies. In epidermolysis 
bullosa acquisita (EBA), in vivo bound immune deposits are below the  integrin of the 
basal keratinocytes membrane and below the components of the lamina lucida and the 
lamina densa (laminin 332 and type IV collagen). A, in a patient with EBA, in vivo bound IgG 
(green) are below type IV collagen (red). B, in a patient with a bullous pemphigoid, in vivo 
bound IgG (green) are above laminin 332 (red). C, in a patient with mucous membrane 
pemphigoid (MMP), in vivo bound IgG (green) are below or colocalize (yellow) with laminin 
332 (red). D, in a patient with MMP, in vivo bound IgG (green) are above or colocalize 
(yellow) with type IV collagen (red) in D. Courtesy of Dr Katarzyna Wozdniak 
Figure 5. Indirect immunofluorescence microscopy with NC1 type VII collagen (NC1-Col7)-
expressing human cells by BIOCHIP™ technology. Patient serum autoAb could label 
molecularly engineered epidermal cells that express human NC1-Col7 on a special slide.  
A, on a standard-sized slide, there are five incubation fields each with two 
different BIOCHIPs: one with HEK293 cells transfected with pTriEx-1 which serve as negative 
control and one with human HEK293 cells transfected with NC1-Col7. B, autoantibodies in 
the serum of a patient with epidermolysis bullosa acquisita labeled NC1-Col7expressing 
HEK293 cells (right image) but not non NC1-Col7expressing cells (left image). C, no reactivity 
of both NC1-Col7 expressing and non NC1-Col7 expressing cells is seen with normal human 
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Figure 6. Immunoblotting (IB) in epidermolysis bullosa acquisita (EBA). By immunoblotting 
with dermal extract, EBA serum recognized a band at 290 kDa which is the alpha chain of 
type VII collagen (Col7), different from laminin 1/ p200 protein. A second band of 145 kDa 
which is the amino-terminal NC1 domain of the alpha chain of Col7 could be seen. NHS, 
normal human serum. 
 
Figure 7. Indirect immunofluorescence (IF) microscopy on type VII collagen (Col7)-deficient 
skin versus normal skin. A, indirect IF microscopy with epidermolysis bullosa acquisita (EBA) 
serum on Col7 containing normal human skin showing positive IgG binding along the 
epidermal basement membrane zone (BMZ) (400x). B, indirect IF microscopy with EBA 
serum on Col7 knockout skin from patient with severe generalized recessive dystrophic 
epidermolysis bullosa showing negative IgG binding along the epidermal BMZ (400x). 
Courtesy of Dr Hendri Pas, Groningen 
 
Figure 8. Indirect immunofluorescence microscopy on salt-split skin. An artificial cleavage is 
induced by NaCl 1M in monkey skin (A, B, counterstained by Evans blue Courtesy of Dr 
Aucouturier, Paris.) or normal human skin (C, D). A, C: labelling of the floor of the cleavage 
by the serum of a patient with EBA. B, D: labelling of the roof of the cleavage by the serum 
of a patient with bullous pemphigoid. 
 
Figure 9:  
Flow chart for diagnosis of epidermolysis bullosa acquisita (EBA). DIF, direct 
immunofluorescence. AIBD, autoimmune blistering disease. Ig, immunoglobulin. DEJ, 
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VII collagen (Col7) specific ELISAs include NC1, NC1/NC2 or full length Col7 ELISAs. The 
BIOCHIP™ technology uses NC1 Col7-transfected HEK293 cells as substrate for indirect 
immunofluorescence (IIF) microscopy (IIFT test). WB, Western blotting. Col7-deficient skin is 
obtained from patients with generalized severe recessive dystrophic epidermolysis bullosa 
(RDEB). MM, mucous membranes. IEM,  immunoelectron microscopy. FOAM, fluorescent 
overlay antigen mapping. LL, lamina lucida. LD, lamina densa.  BP, bullous pemphigoid. 
MMP, mucous membrane pemphigoid. IF, immunofluorescence. SSS, salt split skin: an 
artificial cleavage is obtained by incubation of normal monkey or human skin with NaCl 1M. 
LN, laminin.*, NC1 ELISA, NC1/NC2 ELISA, NC1 Col 7-transfected HEK293 cells and monkey 
SSS are commercially available. † Negativity on Col7 deficient skin is significant if IIF 
microscopy on normal human skin is positive. ‡ include WB with dermal extract or 
recombinant C-terminus LN gamma 1 or IIF on LN 332 deficient skin.  
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Table I: definitions of clinical forms of EBA 
 
Classical/mechanobullous   
One subtype only6 
characterized by 
• trauma induced lesions (skin fragility)* 
• bullous/vesicular lesions or erosions 
• encompassed by non-inflamed or scarred skin. 
• scarring* and milia formation* 
• preferably localized to trauma-prone sites and the extensor skin surface (dorsal 
hands*, elbows*, knees*, Achilles tendon, feet*).  
• possible nail dystrophy* 
• possible scarring alopecia 
  
Non classical/ non mechanobullous 
 
BP- like EBA18, 20-24  
defined as an eruption  
• with features characteristic of BP (pruritus, tense bullae on erythematous or 
urticarial skin, involvement of trunk and folds)  
• usually  mixed with atypical lesions for a BP (skin fragility, bullae on normal skin, 
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MM-EBA20-27  
defined as a disease that predominantly affects MM lined by squamous epithelium, 
i.e MM of 
- mouth,  
- pharynx,  
- oesophagus,  
- epiglottis,  
- conjunctiva,  
- genitalia,  
- anus  
and respiratory tract in malpighian metaplasia 
 
Brunsting-Perry type EBA28-32  
defined as a chronic recurrent blistering dermatosis confined to the head and neck 
 
IgA-EBA20, 33, 34  
defined as a disease that presents with linear IgA deposits in the BMZ that can be 
observed by direct IF 
• it may resemble LABD 
• it may be more aggressive with mucosal scarring 
 
EBA = epidermolysis bullosa acquisita, BP = bullous pemphigoid, MM = mucous membranes, * = 
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